ANTI-INFECTIVE PHARMACOLOGY

Antimicrobial Pharmacology Foundations

Core concept: Effective antimicrobial therapy requires adequate drug exposure at the infection site against a susceptible organism while limiting toxicity and unnecessary selective pressure.

Key clinical distinction: In vitro activity does not guarantee clinical effectiveness. The prescribed regimen must produce sufficient exposure at the infection site, and the patient may also require drainage, debridement, device removal, or another form of source control.

Prescribing priority: Evaluate the pathogen, patient, infection site, and antimicrobial together. A regimen can fail when any one of these elements is inadequately addressed (Ratliff & Oliphant, 2026).

Skip ahead:

Antimicrobials and Selective Toxicity

Antimicrobials interfere with structures or processes that are absent from human cells or sufficiently different to serve as therapeutic targets. This selective toxicity allows treatment of an infectious organism while limiting injury to the patient. Selectivity is relative rather than complete. Toxicity can arise from direct effects on human tissues, immune reactions, interactions, altered elimination, or disruption of the normal microbiome (Ratliff & Oliphant, 2026).

Major categories include:

  • Antibacterials: Target bacterial cell-wall synthesis, protein synthesis, nucleic-acid synthesis, metabolic pathways, or membrane integrity.
  • Antivirals: Interfere with virus-specific stages such as entry, genome replication, integration, protein processing, assembly, or release. Available targets are limited because viruses depend on host-cell processes.
  • Antifungals: Target fungal membranes, cell walls, or nucleic-acid synthesis. Selective toxicity is more difficult because fungi and humans are both eukaryotic organisms.

These categories describe the organism being targeted. They do not establish whether a particular medication is appropriate for the patient, infection site, or suspected pathogen.

The Pathogen, Patient, Drug, and Infection Site

Antimicrobial selection requires integration of four domains.

Pathogen

Evaluate:

  • Likely organism based on the clinical syndrome
  • Gram classification, morphology, and other microbiologic characteristics
  • Expected susceptibility patterns
  • Previous culture results
  • Recent antimicrobial exposure
  • Healthcare, environmental, occupational, and travel exposures
  • Risk factors for resistant organisms
  • Whether an identified organism represents infection, colonization, or contamination

Patient

Assess:

  • Illness severity and physiologic stability
  • Age and body size
  • Immune function
  • Pregnancy or lactation
  • Kidney and liver function
  • Comorbidities
  • Previous antimicrobial exposure
  • Medication allergies and the specific reaction experienced
  • Current medications and potential interactions
  • Ability to obtain, administer, and complete treatment

Drug

Compare:

  • Mechanism of action
  • Spectrum of activity
  • Expected susceptibility
  • Route and bioavailability
  • Pharmacokinetic and pharmacodynamic properties
  • Adverse effects
  • Contraindications and precautions
  • Interaction potential
  • Monitoring requirements
  • Dosing burden
  • Cost and availability

Infection Site

Determine whether the medication can achieve effective exposure in the relevant tissue or fluid. Serum activity does not ensure adequate penetration into the central nervous system, bone, prostate, epithelial lining fluid, abscess cavity, or biofilm-associated infection.

Drug delivery to the infection site may be affected by blood flow, inflammation, protein binding, lipid solubility, molecular size, local pH, tissue barriers, necrosis, foreign material, and route of administration (Ratliff & Oliphant, 2026).

Spectrum of Activity

An antimicrobial’s spectrum describes the organisms against which it has activity.

  • Narrow-spectrum therapy targets a limited group of organisms and may reduce unnecessary exposure of the normal microbiota.
  • Broad-spectrum therapy covers a wider range of organisms and may be necessary when the pathogen is uncertain, resistant organisms are reasonably likely, or the consequences of inadequate initial treatment are substantial.
  • Expanded coverage does not ensure effective treatment. A broad regimen may still omit the causative organism, provide inadequate exposure, or create avoidable toxicity.
  • Spectrum should be narrowed when clinical and microbiologic findings permit more targeted treatment.

Antimicrobial spectrum must be evaluated alongside susceptibility, tissue penetration, dosing, source control, and patient-specific safety (Ratliff & Oliphant, 2026).

Bactericidal and Bacteriostatic Activity

  • Bactericidal agents kill susceptible bacteria.
  • Bacteriostatic agents inhibit bacterial growth and replication, allowing host defenses to participate in organism clearance.
  • These classifications are not absolute. Activity can vary with the organism, drug concentration, infection environment, and laboratory conditions.
  • Bactericidal activity does not make one drug universally superior. Clinical outcomes also depend on susceptibility, exposure, tissue penetration, source control, host defenses, and disease-specific evidence.

Guidelines may favor bactericidal therapy for selected severe or difficult-to-eradicate infections. The classification should be treated as one component of antimicrobial selection rather than an independent prescribing rule (Ratliff & Oliphant, 2026).

Minimum Inhibitory Concentration

The minimum inhibitory concentration, or MIC, is the lowest tested concentration of an antimicrobial that prevents visible growth of an organism under standardized laboratory conditions.

The MIC:

  • Measures inhibition under laboratory conditions
  • Does not directly measure the concentration achieved in the patient
  • Must be interpreted using an organism- and drug-specific breakpoint
  • Cannot be compared across unrelated drugs as though the lowest number identifies the strongest medication
  • Does not account independently for tissue penetration, source control, host response, or toxicity

A lower MIC does not necessarily make one medication clinically preferable to another. The meaning of the value depends on the applicable breakpoint and the exposure produced by the prescribed regimen (Ratliff & Oliphant, 2026).

Susceptibility Categories

Laboratories interpret antimicrobial susceptibility using standardized breakpoints. U.S. reporting may include the following categories:

  • Susceptible: There is a high likelihood of therapeutic success when the recommended regimen is used.
  • Susceptible-dose dependent: The probability of success depends on using a dosing regimen that produces greater drug exposure.
  • Intermediate: The result requires organism- and drug-specific interpretation. Clinical effectiveness may depend on increased exposure or drug concentration at the infection site.
  • Resistant: Treatment failure is likely because the organism is not inhibited by concentrations usually achievable with appropriate therapy.

Not every organism-drug combination has all four categories. Interpretive criteria may also change as pharmacokinetic, pharmacodynamic, resistance, and outcomes data evolve.

“Susceptible” does not mean that the medication is automatically appropriate. The prescriber must still consider the infection site, dose, route, patient characteristics, source control, and clinical evidence (Clinical and Laboratory Standards Institute, 2021; Ratliff & Oliphant, 2026).

Pharmacokinetic and Pharmacodynamic Targets

Antimicrobial effectiveness depends on the relationship between drug exposure and organism susceptibility.

Time-Dependent Activity

Effectiveness is associated with the amount of time that the unbound drug concentration remains above the MIC.

  • Maintaining exposure across the dosing interval is important.
  • More frequent dosing, extended infusion, or continuous infusion may improve target attainment for selected medications and clinical situations.
  • Beta-lactam antibiotics commonly demonstrate time-dependent activity.

Concentration-Dependent Activity

Effectiveness increases as the peak drug concentration rises relative to the MIC.

  • Larger, appropriately spaced doses may produce greater bacterial killing.
  • Some agents continue suppressing bacterial growth after the concentration falls below the MIC. This is called the post-antibiotic effect.
  • Aminoglycosides commonly demonstrate concentration-dependent activity.

Exposure-Dependent Activity

Effectiveness is associated with total drug exposure over time relative to the MIC. This relationship is commonly expressed as the area under the concentration-time curve to MIC ratio.

  • Both the administered dose and the patient’s clearance affect total exposure.
  • Insufficient exposure may contribute to treatment failure.
  • Excessive exposure may increase toxicity.
  • Some agents require therapeutic drug monitoring or individualized dosing to balance effectiveness and harm.

These categories describe dominant exposure-response relationships. Medication-specific dosing recommendations and the patient’s clinical condition remain central to regimen selection (Ratliff & Oliphant, 2026).

Tissue Penetration and Distribution

A laboratory report showing susceptibility does not establish that the drug will reach the infection site in an effective concentration.

Penetration may be limited by:

  • Reduced blood flow
  • Tissue barriers
  • Protein binding
  • Molecular size
  • Lipid solubility
  • Local pH
  • Abscess formation
  • Necrotic tissue
  • Foreign material
  • Biofilm
  • Organ dysfunction

Inflammation may increase penetration into some compartments, while abscesses, necrotic tissue, and biofilms can reduce antimicrobial activity. An apparently active medication may therefore fail if its distribution does not match the anatomy of the infection. Inadequate source control can also prevent clinical resolution even when the organism is susceptible and the antimicrobial reaches the infection site (Ratliff & Oliphant, 2026).

Patient-Specific Selection and Monitoring

Antimicrobial selection must account for patient characteristics that influence drug exposure, treatment response, and the risk of harm. Relevant factors include age, pregnancy or lactation, allergy history, immune status, renal and hepatic function, previous antimicrobial exposure, concurrent medications, and the feasibility of completing the prescribed regimen. Renal or hepatic impairment may require dosage adjustment, while immunocompromised patients may need broader initial coverage, bactericidal therapy, or a longer treatment duration depending on the infection and clinical response (Ratliff & Oliphant, 2026).

Monitoring should be matched to the antimicrobial, infection severity, treatment duration, and patient risk factors. The plan may include assessment of symptom resolution, temperature, hemodynamic stability, organ function, inflammatory markers, culture and susceptibility results, drug concentrations, adverse effects, and evidence of secondary infection. Failure to improve should prompt reassessment of the diagnosis, source control, adherence, drug exposure, tissue penetration, resistance, and the possibility that the selected organism is not the true cause of illness (Ratliff & Oliphant, 2026).

Mechanisms of Antimicrobial Resistance

Resistance may be intrinsic, meaning naturally present in the organism, or acquired through mutation or transfer of genetic material.

Important mechanisms include:

  • Enzymatic destruction or modification of the drug
  • Alteration or protection of the drug target
  • Reduced membrane permeability
  • Active efflux
  • Bypass of the inhibited metabolic pathway
  • Target overproduction
  • Biofilm-associated protection

Resistance mechanisms can coexist. An organism may also acquire resistance to several medications through linked genetic elements, producing multidrug resistance.

Antimicrobial exposure creates selective pressure by suppressing susceptible organisms while allowing resistant organisms to survive and proliferate. Unnecessary or prolonged exposure increases this pressure. In some pathogen-drug combinations, subtherapeutic exposure or incomplete adherence may permit continued replication and selection of resistant organisms. The effect varies by pathogen, medication, infection site, and resistance mechanism (Ratliff & Oliphant, 2026).

Combination Therapy

More than one antimicrobial may be used to:

  • Provide adequate initial coverage during severe infection
  • Treat a polymicrobial infection
  • Produce synergistic activity
  • Prevent or delay resistance during treatment of selected infections
  • Address organisms requiring different mechanisms of action

Combination therapy can also increase toxicity, interactions, cost, and disruption of the microbiome. Each medication should have a defined purpose. Combination therapy should be reassessed when microbiologic and clinical findings clarify what coverage is required (Ratliff & Oliphant, 2026).

Connection to Antimicrobial Stewardship

These pharmacologic principles provide the foundation for antimicrobial stewardship. Appropriate prescribing requires confirmation of the treatment indication, selection of an active regimen that reaches the infection site, adequate drug exposure, and reassessment as clinical and microbiologic information becomes available. The CDC’s outpatient stewardship framework extends these decisions through organizational commitment, accountability, expertise, clinical action, measurement, reporting, and education (Centers for Disease Control and Prevention, 2026).

Detailed application of these principles belongs on the separate Antimicrobial Selection and Stewardship page.

High-Yield Clinical Distinctions

  • A positive culture does not independently establish infection.
  • In vitro susceptibility does not guarantee clinical effectiveness.
  • Broad-spectrum therapy is not inherently more effective than targeted therapy.
  • A bactericidal drug is not automatically superior to a bacteriostatic drug.
  • The MIC cannot be interpreted without the applicable breakpoint.
  • “Susceptible” does not mean that any dose will be effective.
  • Serum activity does not ensure adequate tissue penetration.
  • Failure to improve does not automatically indicate antimicrobial resistance.
  • Effective antimicrobial therapy cannot compensate for inadequate source control.

Content last reviewed:

↑

References

Centers for Disease Control and Prevention. (2026, August 3). Core elements of outpatient antibiotic stewardship. https://www.cdc.gov/antibiotic-use/hcp/core-elements/outpatient-antibiotic-stewardship.html

Clinical and Laboratory Standards Institute. (2021, April 26). Re-exploring the intermediate interpretive category. https://clsi.org/about/blog/re-exploring-the-intermediate-interpretive-category/

Ratliff, A., & Oliphant, C. (2026). Patient assessment, antimicrobial selection, and stewardship. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed.). McGraw Hill. https://ppp.mhmedical.com/book.aspx?bookid=3598